Literature DB >> 31414022

Coordinating an Oncology Precision Medicine Clinic Within an Integrated Health System: Lessons Learned in Year One.

Michael A Thompson1,2, Jennifer J Godden2, Deborah Wham2, Antony Ruggeri2, Michael P Mullane2, Amanda Wilson3, Shamsuddin Virani2, Scott M Weissman2,4, Brenda Ramczyk2, Pamela Vanderwall2, James L Weese2.   

Abstract

Precision medicine is a term describing strategies to promote health and prevent and treat disease based on an individual's genetic, molecular, and lifestyle characteristics. Oncology precision medicine (OPM) is a cancer treatment approach targeting cancer-specific genetic and molecular alterations. Implementation of an OPM clinical program optimally involves the support and collaboration of multiple departments, including administration, medical oncology, pathology, interventional radiology, genetics, research, and informatics. In this review, we briefly introduce the published evidence regarding OPM's potential effect on patient outcomes and discuss what we have learned over the first year of operating an OPM program within an integrated health care system (Aurora Health Care, Milwaukee, WI) comprised of multiple hospitals and clinics. We also report our experience implementing a specific OPM software platform used to embed molecular panel data into patients' electronic medical records.

Entities:  

Keywords:  community; genomics; integrated health system; oncology; precision medicine

Year:  2019        PMID: 31414022      PMCID: PMC6676755          DOI: 10.17294/2330-0698.1639

Source DB:  PubMed          Journal:  J Patient Cent Res Rev        ISSN: 2330-068X


  16 in total

1.  Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers.

Authors:  Daniel D Von Hoff; Joseph J Stephenson; Peter Rosen; David M Loesch; Mitesh J Borad; Stephen Anthony; Gayle Jameson; Susan Brown; Nina Cantafio; Donald A Richards; Tom R Fitch; Ernesto Wasserman; Cristian Fernandez; Sylvan Green; William Sutherland; Michael Bittner; Arlet Alarcon; David Mallery; Robert Penny
Journal:  J Clin Oncol       Date:  2010-10-04       Impact factor: 44.544

2.  Precision medicine: lessons learned from the SHIVA trial.

Authors:  Apostolia M Tsimberidou; Razelle Kurzrock
Journal:  Lancet Oncol       Date:  2015-12       Impact factor: 41.316

3.  Can We Define and Reach Precise Goals for Precision Medicine in Cancer Care?

Authors:  Howard Jack West
Journal:  J Clin Oncol       Date:  2016-10-20       Impact factor: 44.544

4.  The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer.

Authors:  Vassiliki Papadimitrakopoulou; J Jack Lee; Ignacio I Wistuba; Anne S Tsao; Frank V Fossella; Neda Kalhor; Sanjay Gupta; Lauren Averett Byers; Julie G Izzo; Scott N Gettinger; Sarah B Goldberg; Ximing Tang; Vincent A Miller; Ferdinandos Skoulidis; Don L Gibbons; Li Shen; Caimiao Wei; Lixia Diao; S Andrew Peng; Jing Wang; Alda L Tam; Kevin R Coombes; Ja Seok Koo; David J Mauro; Eric H Rubin; John V Heymach; Waun Ki Hong; Roy S Herbst
Journal:  J Clin Oncol       Date:  2016-10-20       Impact factor: 44.544

5.  Influence of decalcification procedures on immunohistochemistry and molecular pathology in breast cancer.

Authors:  Willemijne A M E Schrijver; Petra van der Groep; Laurien Dc Hoefnagel; Natalie D Ter Hoeve; Ton Peeters; Cathy B Moelans; Paul J van Diest
Journal:  Mod Pathol       Date:  2016-08-26       Impact factor: 7.842

Review 6.  Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials.

Authors:  Maria Schwaederle; Melissa Zhao; J Jack Lee; Alexander M Eggermont; Richard L Schilsky; John Mendelsohn; Vladimir Lazar; Razelle Kurzrock
Journal:  J Clin Oncol       Date:  2015-08-24       Impact factor: 44.544

7.  Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.

Authors:  Christophe Le Tourneau; Jean-Pierre Delord; Anthony Gonçalves; Céline Gavoille; Coraline Dubot; Nicolas Isambert; Mario Campone; Olivier Trédan; Marie-Ange Massiani; Cécile Mauborgne; Sebastien Armanet; Nicolas Servant; Ivan Bièche; Virginie Bernard; David Gentien; Pascal Jezequel; Valéry Attignon; Sandrine Boyault; Anne Vincent-Salomon; Vincent Servois; Marie-Paule Sablin; Maud Kamal; Xavier Paoletti
Journal:  Lancet Oncol       Date:  2015-09-03       Impact factor: 41.316

8.  Proposal of an appropriate decalcification method of bone marrow biopsy specimens in the era of expanding genetic molecular study.

Authors:  Sung-Eun Choi; Soon Won Hong; Sun Och Yoon
Journal:  J Pathol Transl Med       Date:  2015-05-15

Review 9.  Role of rebiopsy in relapsed non-small cell lung cancer for directing oncology treatments.

Authors:  Antti P Jekunen
Journal:  J Oncol       Date:  2015-01-29       Impact factor: 4.375

10.  Clinical benefit of a precision medicine based approach for guiding treatment of refractory cancers.

Authors:  Milan Radovich; Patrick J Kiel; Stacy M Nance; Erin E Niland; Megan E Parsley; Meagan E Ferguson; Guanglong Jiang; Natraj R Ammakkanavar; Lawrence H Einhorn; Liang Cheng; Mehdi Nassiri; Darrell D Davidson; Daniel A Rushing; Patrick J Loehrer; Roberto Pili; Nasser Hanna; J Thomas Callaghan; Todd C Skaar; Paul R Helft; Safi Shahda; Bert H O'Neil; Bryan P Schneider
Journal:  Oncotarget       Date:  2016-08-30
View more
  2 in total

1.  Personalised medicine and the decision to withhold chemotherapy in early breast cancer with intermediate risk of recurrence - a systematic review and meta-analysis.

Authors:  Susanna M Wallerstedt; Astrid Nilsson Ek; Roger Olofsson Bagge; Anikó Kovács; Annika Strandell; Barbro Linderholm
Journal:  Eur J Clin Pharmacol       Date:  2020-06-05       Impact factor: 2.953

Review 2.  Germline testing and genetic counselling in prostate cancer.

Authors:  Jessica Russo; Veda N Giri
Journal:  Nat Rev Urol       Date:  2022-04-21       Impact factor: 16.430

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.